Phase 4 N=52 Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols
Dyslipidemias · Hypercholesterolemia
Primary: Serum LDL Cholesterol — 122.2; 113.5 mg/dl
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Effect of Diabetes Mellitus on Cholesterol Metabolism
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus · Hypercholesterolemia
Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L
Phase 3 N=145 High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
Atherosclerosis · Cardiovascular Disease
Primary: Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries — 7; 5 percentage of internal…
N/A N=88 Effect of a Treatment With a Nutraceutical Combination on Sub-optimal LDL Cholesterol Levels
Hypercholesterolemia
Primary: Change in Blood LDL Cholesterol Level — -32.48; 2.54 mg/dL — p=<0.0001
Phase 3 N=1,053 Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001
Phase 2 N=527 A Study of LY3015014 in Participants With High Cholesterol
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) — 7.6; -14.9; -40.5; -50.5 Percentage change
Phase 3 N=58 A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
Hypercholesterolemia
Primary: Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test Meal — 0.45; 0.50 mg/dL — p=0.241
Phase 1 N=13 A Study of LY3015014 in Healthy Participants With High Cholesterol
Healthy Volunteers · Hypercholesterolemia
Primary: Number of Participants With One or More Other Non-Serious Adverse Events (AEs) or Any Serious AEs (SAEs) — 3; 1; 0; 0 Participants
Phase 2 N=54 Preliminary Study of Safety and Efficacy of Policosanol
Dyslipidemia · HIV Infections
Primary: LDL Cholesterol — 116.34; 118.84 mg/dl
N/A N=57 The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux
Lipid Metabolism Disorders
Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio
Phase 3 N=20 Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Metabolic Syndrome X
Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene
Phase 2 N=398 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
Dyslipidemia
Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…
N/A N=111 Study of Cholesterol Levels and Types in African Americans With Type 2 Diabetes
Type 2 Diabetes · African American · Cholesterol
Primary: ApoB Levels in African American Men With Diabetes and Those Without. — 80; 65 mg/dL — p==0.002
Phase 2 N=86 Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Cardiovascular Disease
Primary: Total Serum Cholesterol Levels for Alpha-cyclodextrin (a-CD) and Placebo Groups After 12-14 Weeks, Compared to Baseline — 180; 180 mg/dL — p=0.82
Phase 3 N=579 To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
Hypercholesterolemia
Primary: Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C — -27.4; -11.0 Percent Change — p=<0.001
Phase 3 N=1,547 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I) — -24.8; -10.1; -13.8 Percentage Change — p=<0.001
Phase 4 N=25 Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
Coronary Heart Disease
Primary: Cholesteryl Ester Fractional Clearance Rate
Phase 2 N=34 Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Metabolic Diseases · Hyperlipidemias · Metabolic Disorder
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -2.0; -47.3 percentage of baseline — p=<0.001
N/A N=1,682 Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
Hypercholesterolemia
Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants
Phase 2 N=354 Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin
Hypercholesterolemia
Primary: Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -2.6; -36.9; -47.6; -56.0 milligram per deciliter (mg/dL) — p=<0.001
Phase 2 N=199 Supplements, Placebo, or Rosuvastatin Study
Hypercholesterolemia
Primary: Percent Change in LDL-C From Baseline for Rosuvastatin 5mg Daily Compared With Placebo and Each Dietary Supplement. — -37.86; -2.63; -3.43; 0.42 percent change LDL-C…
Phase 3 N=196 To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 — -30.8; -10.9 Percent — p=<0.001
Phase 2 N=176 A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
Type II Hyperlipidemia
Primary: Percent Change in HDL-C From Baseline — 3.2; 84.2; 122.1; 160.6 percent change from baseline
N/A N=10 Choline and Cardiometabolic Health
Cardiovascular Risk Factor
Primary: Change From Baseline in Insulin Sensitivity at 4 Weeks — 0.28; -0.29 Calculated Ratio - No units
N/A N=27 How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
Phase 3 N=646 Effect of MK0524A on Cholesterol Levels (0524A-048)
Hypercholesterolemia · Hyperlipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) After 12 Weeks — -10.3; 4.4 Percent Change — p=<0.001
Phase 2 N=25 ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
Dyslipidemia
Primary: Mean Change in Calculated Low Density Lipoprotein Cholesterol — -22.7 mg/dL — p=0.0042
Phase 1 N=51 A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol
Healthy Volunteers
Primary: Number of Participants With 1 or More Drug Related Treatment-Emergent Adverse Events (TEAEs) or Any Serious AEs (SAEs) — 4; 3; 5; 2 Participants
Phase 3 N=1,143 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
Hypercholesterolemia · Metabolic Syndrome
Primary: Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6 — -36.5; -49.6; -39.4; -53.9 Percent Change — p=<0.001
Phase 2 N=36 Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia
Hypercholesterolemia · Hyperlipoproteinemia Type II
Primary: Number of Participants Who Incurred at Least One Treatment Emergent Event — 33; 10 participants